Clinics in Laboratory Medicine 1991: Vol 11 Index

21 Pages·1991·3.8 MB·English

Cumulative Index 1991
Volume 11
March LABORATORY AND HOSPITAL INFORMATION SYSTEMS,
pages 1-270
June VALUE AND LIMITATIONS OF CYTOLOGIC EXAMINATIONS,
pages 271-508
September LABORATORY TESTING IN ORGAN TRANSPLANTATION,
pages 509-810
December DIAGNOSIS OF IMPORTANT PARASITIC DISEASES,
pages 811-1089
Note: Page numbers for complete issues and articles appear in boldface type.
ABEL expert system, 145 Adenocarcinoma, cytology in, bile duct, 338,
ABO blood group incompatibility, in graft 340
rejection, 538, 544, 592 cervical, 282-286
Abscess, amebic, 849-850 colon, 424-429, 435
cytology in, breast, 358-359 effusion, 450-451
head and neck, 334 endometrial, 286-289
liver, 343 esophageal, 408-409
lung, 311 extrauterine, 289-290
Acanthamoeba, in dermatitis, 871 gastric, 418-419
in granulomatous encephalitis, 861-866 ilnu nlgi,v er3 0m1e-t3a0s6t asis, 341
in keratitis, 870-871
in pneumonitis, 871 pancreatic, 345, 347
Accounting, information systems for, 87-88, prostate, 388-389, 391
vs. adenoma, 435
166
Adenocarcinoma in situ, cervical, cytology
Accreditation. See Laboratory regulation.
in, 283-284
Acid-base electrolyte program (ABEL), 145
Adenoid cystic carcinoma, of salivary glands,
Acinar cell carcinoma, pancreatic, cytology
cytology in, 329
in, 349
Adenoma, cytology in, colon, 434—436
Acinic cell carcinoma, of salivary glands, gastric, 421-422
cytology of, 329, 331 hepatocellular, 340
Acquired immunodeficiency syndrome, pancreatic, 351
pulmonary cytology in, 295-296, 310- salivary glands, 326-327
313 thyroid, 318-319
toxoplasmosis in, 934-935 Affinity column-mediated immunoassay, in
Acute-phase proteins, in liver graft cyclosporine A monitoring, 678
rejection, 662 African trypanosomiasis, 899-905
Acute tubular necrosis, urinary sediment clinical features of, 902
cytology in, 745 epidemiology of, 901-902
1070 CUMULATIVE INDEX 1991
African trypanosomiasis (C: ontinued ) staining in, 838-839, 842-844
laboratory diagnosis of, 903-905 temporary wet mounts in, 837-839
late stage, 904-905 epidemiology of, 830
organisms causing, 899, 901 extraintestinal, 849-850
trypanotolerance in, 902-903 of liver, 849-850
Agglutination test. See also parasite of (Entamoeba histolytica), 829-
Hemagglutination test. 830
direct, in leishmaniasis, 920 cysts of, 829-830, 846-847
in toxoplasmosis, 928-929 hematophagous form of, 830
immunosorbent, in toxoplasmosis, 930 in vitro cultivation of, 847-849
in trypanosomiasis, 903 morphology of, 844-847
latex, in toxoplasmosis, 929 trophozoites of, 829-830, 844-846
Alkaline phosphatase levels, in liver graft American trypanosomiasis, 905-908
monitoring, 658-659 Amphotericin B, in amebic
Alloantibodies. See also Antibody(ies), in meningoencephalitis, 866
transplantation, donor-specific. Amylase, in pancreas graft rejection, 663
removal of, before transplantation, 544 ANA-BEL expert system, 145
to HLA, anti-idiotypic-like, 633-652 Anal intraepithelial neoplasia, cytology in,
laboratory detection of, 640-642 430-431
networks in, 637-640 Analysis of Acid-Base Status by Evaluating
relevance of, 643-645 Lisp system, 145
T-cell regulation and, 646-647 Anaplastic carcinoma, thyroid, cytology in,
terminology of, 635-637 322
cell panel for, 556-557 Angiomyolipoma, renal, cytology in, 384
characteristics of, 552-555 Angiosarcoma, liver, cytology in, 340
crossmatching strategy and, 564-567 Animal pathogenicity tests, in free-living
screening interpretation of, 563-564 amebic infections, 865
screening procedures for, 555-562 Anion exchange centrifugation test, in
screening strategy for, 562-563 African trypanosomiasis, 904
Alloantigens, presensitization to, 543-544 Anti-human-globulin-augmented cytotoxicity
T-cell receptor recognition of, 540-541 test, in crossmatching, 610
T-cell response to, in graft rejection, 539-
Anti-idiotypic antibodies, definition of, 636-
540 637
Allograft rejection. See Graft rejection.
development of, 638-640
Alloimmunization. See also Alloantibodies.
predictive testing in, 768-769 in alloimmunization. See under Alloanti-
to HLA, 551-570 bodies.
in pretransplant enhancement, 644-645
epitopes in, 552-555
laboratory detection of, 640-642
in crossmatch procedures, 607
nonsite-associated, 636
induction of, 552
posttransplant, 589, 591-592
loss of, monitoring of, 643-644
private epitopes in, 552-555 site-associated, 636
public epitopes in, 552-555 testing for, 578-579
Amastigotes, visualization of, in to OKT3, development of, 700-703
leishmaniasis diagnosis, 912-917 Anti-isotype antibodies, to OKTS,
Amebas, free-living, 861-872 development of, 702-703
in acanthamoebic infections, 870-871 Anti-mouse immunoglobulin G antibodies,
in granulomatous amebic encephalitis, interference with OKTS assays, 768
866-870 Anti-OKTS3 antibodies, development of,
in meningoencephalitis, 861-866 700-703
Amebiasis, 829-859 Antibody(ies), in transplantation, donor-
diagnosis of, antigen detection in, 853— specific, 571-602
anti-Cw-induced rejection, 581
circulating immune complexes in, 853 anti-idiotypic, 578-579, 589
immunoglobulin M detection in, 853 autolymphocytotoxic, 588
immunologic methods in, 850-852 definition of, 572
molecular technology in, 854 endothelial antigen system in, 576—
specimen collection for, 831-832 578, 587-588
specimen concentration for, 840-842 epithelial antigen system in, 576-578
specimen preservation for, 832-836 in hyperacute rejection, 581
CUMULAITNDIEXV 1E99 1 1071
in predicting positive crossmatches, in HLA alloantibody screening, 555-556,
579-580 559-562
induction of, 571-572 Apocrine carcinoma, breast, cytology in, 367
low-affinity, 588, 592 Asbestos bodies, in pulmonary cytology, 313
management of highly sensitized pa- Aspergillosis, pulmonary cytology in, 312
tients in, 582-583 Aspiration, needle. See Needie aspiration.
monocyte expression of, 576-578 Atherosclerosis, in heart graft, 589
of heart, 585-589 Australia, laboratory regulation in, 777-791
of kidney, 573-585 accreditation authorities for, 781-784
of liver, 590-593 Commonwealth Department of Com-
of pancreas, 593-595 munity Services and Health in,
poor match consequences and, 580- 781-782
581 education authorities in, 788-790
positive donor lymphocyte cross- history of, 778-779
match in, 573-576, 585-587, inspecting authorities in, 786-788
590-591, 593 National Pathology Accreditation Advi-
posttransplant, 581-582, 588-589, sory Council in, 779-781
591-592, 644 payment authorities in, 784—786
removal of, 582 quality assurance program authorities
repeat antigen mismatch and, 580 in, 788
suppression of, 582 pretransplant staff qualifications and, 783-784
transfusions in, 633-634, 644— standards authorities for, 779-781
645 Victorian Pathology Services Accredita-
to Giardia, 821-823 tion Board in, 782-783
Australian Association of Clinical
to non-HLA antigens. See under Anti-
gen(s), non-HLA. Biochemists, 789
Antibody-dependent cell-mediated Australian Institute of Medical Laboratory
cytotoxicity test, in kidney graft Scientists, 789
monitoring, 737 Australian Society for Microbiology, 790
Antibody detection tests, in cysticercosis, Autoantibodies, adsorption of, in crossmatch
1018 procedures, 608
in filariasis, 994-996, 998, 1002, 1005 Autoimmunization, to HLA, in crossmatch
procedures, 607
in pneumocystosis, 970
Autolymphocytotoxic antibodies, in
Antigen(s), HLA. See HLA.
crossmatch procedures, 607—608
non-HLA, antibodies to, 621-632
in heart transplantation, 588
clinical significance of, 629
Automation, information systems in. See
gamma interferon effects on, 627
Information systems.
in B cells, 628
in endothelial cells, 622-624, 626
in graft rejection, 622
in keratinocytes, 626-627 B cell(s), endothelial antigens expressed on,
in monocytes, 624, 627-628 628
skin crossmatching and, 625 enrichment with, for crossmatch proce-
characteristics of, 628-629 dures, 606
prior mismatch of, graft survival and, 580 Bacteremia, in liver transplantation, vs.
to Entamoeba, detection of, 853-854
rejection, 656
Antigen detection tests, in cysticercosis, Bacterial infections, in transplant patients,
1017 720
in filariasis, 999-1000, 1005 Bar codes, in information systems, 227-238
in free-living amebic infections, 864 applications of, 234-236
in pneumocystosis, 970-971 barriers to, 236-237
in toxoplasmosis, 931 blood bank labelling with, 235
Antigen-presenting cells, allogeneic, in graft clinical laboratory, 231-233
rejection, 539-540 industrial, 231
Antigen-trapping ELISA technique, in patient identification with, 234-235
African trypanosomiasis, 903 readers for, 230-231
Antiglobulin-augmented complement- standard structure for, 236-237
dependent cytotoxicity assay, in anti- symbolology in, 228-229
idiotypic antibody detection, 641-642 Barrett's dysplasia, cytology in, 412—413
1072 CUMULATIVE INDEX 1991
Barrett's esophagus, cytology in, 407-408 in pneumocystosis diagnosis, 961
BASIC language, 30-31, 56 Brugia malayi infection. See Filariasis.
Benign lymphoepithelial lesion, of salivary Brush cytology, bronchial, 295
glands, cytology in, 331 in colon adenocarcinoma, 425—429
Beta—2-microglobulin, in liver graft in gynecology, 273
rejection, 662 in ulcerative colitis, 432-433
Bethesda system, for gynecologic cytology, Burkitt’s lymphoma, cytology in, 481—482
273-279
Bile cytology, in liver graft monitoring, 661
Bile duct adenocarcinoma, cytolegy in, 338,
340 C-dependent cytotoxicity assay, 555-556,
Bilirubin levels, in liver graft monitoring, 609-610, 737
658-659 C language, 59, 62, 69
Billing, for hospital-based pathology Candidiasis, esophageal, cytology in, 404
services, 1052-1054, 1060-1061 in transplant patients, 724
for hybrid laboratories, 161-166 Carcinoid tumors, of stomach, cytology in,
Biochemical diagnosis, of malaria, 951 422-493
Biopsy, in graft monitoring, before OKT3 Carcinoma. See also Adenocarcinoma.
therapy, 707 acinar cell, cytology in, 349
endomyocardial, 663-664, 742 acinic cell, cytology in, 329, 331
fine needle aspiration, 655-659, 663, adenoid cystic, cytology in, 329
743-744 anaplastic, of thyroid, cytology in, 322
liver, 655-659 apocrine, cytology in, 367
pancreas, 663 breast, cytology in, 362-367
in pneumocystosis diagnosis, 961, 963 bronchiolar, cytology in, 301-306
needle. See Needle aspiration. colon, metastasis to liver, 341
of leishmaniasis lesion, 916-917 cyst-containing, cytology in, 334
of skin, microfilariae detection in, 984— effusions in, 448—454
985 follicular, of thyroid, cytology in, 319
BK papovavirus infection, in transplant hepatocellular, cytology in, 337-338
patients, 721 large-cell. See Large-cell carcinoma.
Bladder, tumors of, cytology in. See lung. See Pulmonary cytology.
Urinary cytology. medullary. See Medullary carcinoma.
washing of, urine specimen from, 375 metastatic, cytology in, to liver, 340-342
Blood, in pulmonary cytology, 312-313 to neck lymph nodes, 334
lymphocyte isolation from, for transplanta- mucinous, cytology in, 367
tion crossmatching, 605 mucoepidermoid, cytology in, 327, 329
Blood bank, bar code labelling in, 235 oat-cell. See Small-cell carcinoma.
Blood smear, stained, in filariasis diagnosis, pancreatic, cytology in, 349-351
979-981 papillary. See Papillary carcinoma.
Boech and Drobhlav’s medium, for amebae renal cell, cytology in, 382, 384, 386
cultivation, 848 signet-ring, cytology in, 451
Branchial cleft cyst, cytology in, 334 squamous cell. See Squamous cell carci-
Breast lesions, cytology of, 357-368 noma.
benign, 359-362 thyroid, cytology in, 319-322
malignant, 362-367 transitional cell, urinary cytology in, 377,
metastasis to liver, 341 381
nonneoplastic, 358-359 undifferentiated, cytology in, effusion, 454
technique for, 357 esophageal, 414
vs. normal tissue, 358 urinary tract. See Urinary cytology.
Bronchial atypia, vs. adenocarcinoma, 303- Carcinoma in situ, cytology in, bladder, 373,
306 376
Bronchial brushings/washings, for cytology, cervical, 277, 279
295 Card agglutination trypanosomiasis test, 903
Bronchiectasis, cytology in, 311 Carotid body paraganglioma, cytology in,
Bronchiolar carcinoma, cytology in, 301-306 333
Bronchitis, cytology in, 311 Catheterization, urine specimen from, 375
Bronchoalveolar lavage, cytology of, 295- Cavernous hemangioma, of liver, cytology
296 in, 340
in lung graft monitoring, 664-665 CD cells. See under Lymphocyte(s).
CUMULAITNDIEXV 1E99 1 1073
Cell-mediated lympholysis, in HLA typing, anal intraepithelial neoplasia, 430-431
514, 544 carcinoma, metastatic to liver, 341
Cellophane tape test, in cysticercosis, 1019 cytomegalovirus colitis, 429-430
Centrifugation, in African trypanosomiasis Kaposi's sarcoma, 436
diagnosis, 904 ulcerative colitis, 431-434
in filariasis diagnosis, 981 Commercialism, in laboratory regulation,
in malaria diagnosis, 950-951 800-801
Cerebrospinal fluid examination, in African Commonwealth Department of Community
trypanosomiasis, 904—905 Services and Health Accreditation
in cysticercosis, 1016-1018 Branch (Australia), 781-782
in granulomatous amebic encephalitis, Communication, in information systems. See
867-868 under Information systems.
Cervical disorders, cytology in, Competitors, of hospital laboratories. See
adenocarcinoma, 282-286 under Hospital laboratories.
carcinoma in situ, 277, 279 Complement, in kidney graft rejection, 737
human papillomavirus lesions, 281-282 Complement-dependent cytotoxicity assay,
small-cell carcinoma, 279-280 in anti-idiotypic antibody detection,
squamous cell carcinoma, 280-282 641-642
Cervical epithelial lesions, microinvasive in kidney graft monitoring, 737
squamous cell carcinoma, 280 in transplantation crossmatching, 609-610
preneoplastic/early neoplastic, 273-280 Complement factor analysis, expert systems
classification of, 275-276 for, 145-146
cytologic features of, 277, 279 Complement fixation test, in American
cytoplasmic differentiation of, 279-280 trypanosomiasis, 906
histopathology of, 276-277 in toxoplasmosis, 928
keratinization of, 279 Computed tomography, in cysticercosis,
Cervical intraepithelial neoplasia 1015
classification system, 276 Computerized Laboratory Alerting System
(CLAS), 148
Cervicovaginal cytology. See Gynecologic
cytology. Computers, acquisition of, 1-20
Chagas disease, 905-908 general principles of, 1-7
Chemiluminescence immunoassay, in vendor selection in, 21-39
cyclosporine A monitoring, 678 aversion to, 49
Chemotherapy, cell changes in, bladder, compilers in, 6-7, 56
380 components of, 54-55
esophagus, 411-412 dialogue with, 17
prostate, 392 display features of, 14-15, 131-132
Chlamydial infection, cytology in, 282 error messages of, 16
Chloroma, cytology in, 488-489 flexibility of, 13-14
Cholangiocarcinoma, cytology in, 338, 340 friendliness of, 13-14
Cholestasis, in liver graft, vs. rejection, 658 graphical user interface in, 126-128
Chromatography, high performance liquid, hardware risks in, 30
in cyclosporine A monitoring, 675-676 in workstations. See Information systems,
Chromium-release assays, in transplantation workstations for.
crossmatching, 615 input devices for, 126
Circulating immune complexes, in interpreters in, 56
transplantation, 579 life cycle of, 6-7
Cirrhosis, cytology in, 343 maintenance of, 37-38, 48
CLAS expert system, 148 output devices for, 126
COBOL, 7, 30-31, 56, 68-69 performance limits of, 70-71
Codes, bar. See Bar codes. personal, languages for, 59-60
for pathology services billing, 1057-1060 learning from, 2-3
Colitis, cytology in, cytomegalovirus, 429- programming languages for. See Lan-
430 guages, programming.
ulcerative, 431-434 reliability of, 15
Colloid goiter, cytology in, 318 requirements of, 13-17
Colon disorders, cytology in, 424-436 software for. See Software.
adenocarcinoma, 424—429 strengths of, 3-5
metastatic to lung, 301-303 user interface of, 126-128
adenoma, 434—436 weaknesses of, 3-5
1074 CUMULATIVE INDEX 1991
Computers (Continued) Cyclosporine A monitoring, in
windowing systems in, 127-128 transplantation, 671-691
Concavalin A test, in kidney graft affinity column-mediated immunoassay
monitoring, 738 in, 678
Concentration procedures, for filariasis area under curve, 686-687
diagnosis, 981-984 chemiluminescence immunoassay in,
for stool specimen, 819, 840-844, 884 678
Condylomata, human papillomavirus, dilemmas in, 672-674
cytology in, 281-282 enzyme-multiplied immunoassay in, 678
Consultation, for information systems, 8-9 fluorescence polarization immunoassay
Contract, for information system acquisition, in, 677-678
34-39 high performance liquid chromatogra-
for pathology services, 1052 phy in, 675-676
Coproantigen detection, in cysticercosis, lymphokine assay in, 752, 754, 756-757
1020 metabolite interference in, 673-674
Costs, of information systems. See under methods for, 674-678
Information systems. correlations among, 684
Cough induction, for sputum cytology, 294 pharmacokinetics in, 686-687
Counterimmunoelectrophoresis, in radioimmunoassay in, 674-677
American trypanosomiasis, 906-907 sample matrix for, 672-673
in giardiasis, 822 trough, 686
Crossmatch procedures, in transplantation, urinary sediment cytology in, 745-749
603-620, 766-767. See also Cyst(s), Entamoeba, 829-830, 847-848
Mismatch. Giardia, 813, 816
chromium-release assays in, 615 Cystadenoma, serous, of pancreas, cytology
clinical relevance of, 615-617 in, 351
complement-dependent cytotoxicity as- Cystic lesions, cytology in, breast, 359
says in, 609-610 liver echinococcus cyst, 343
donor-specific antibodies and, 573-576, neck, 334
579-580 pancreas, 351
flow cytometry in, 610-615 renal, 384-385
historical aspects of, 604 Cysticercosis, 1011-1028
HLA typing, 734-735 clinical diagnosis of, 1014-1015
in HLA alloimmunization, 564-567 epidemiology of, 1012, 1014
negative results in, early allograft rejec- laboratory diagnosis of, fecal examination
tion in, 622 in, 1018-1020
positive results in, vs. hyperacute rejec- future prospects for, 1023
tion, 586-587 immunologic, 1015-1018
practical considerations for, 541-542 lumbar puncture in, 1018
recipient sera for, 607-608 parasite of, 1011-1012, 1014
skin samples for, 625-629 pathogenesis of, 1012
target cell isolation in, 604-606 public health aspects of, 1022-1023
Crossreactivity, of HLA class I, 516-517 radiologic diagnosis of, 1015
Cryptococcosis, in transplant patients, 725 tissue diagnosis of, 1020-1021
Cryptosporidiosis, 873-897 transmission of, 1011-1012
clinical features of, 882-883 treatment of, 1021-1022
diagnosis of, histologic, 883 Cystosarcoma phyllodes, of breast, cytology
laboratory, 883-887 in, 360
epidemiology of, 878-881 Cystoscopy, urine specimen from, 375
etiologic agent of, 876-878 Cytobrush, in gynecologic cytology, 273
in HIV-infected persons, 881 Cytoimmunologic monitoring, of heart graft,
parasite of, life cycle of, 876-878 664, 742-743
sources of, 880 Cytology, breast, 357-368
taxonomic relationships of, 876 bronchial, 295
prevalence of, 880-881 bronchoalveolar lavage, 295-296
transmission of, 878-880 cervicovaginal, 271-292
treatment of, 887-889 colon, 424-436
Culture, of Entamoeba histolytica, 848-849 effusion, 443-467
of Leishmania, 917-919 esophageal, 404—415
Cyclophosphamide, in OKT3 therapy, 709 gastrointestinal, 403-441
CUMULAITNDIEXV 1E99 1 1075
genitourinary, 369-401 E-M antigens, in transplantation testing,
gynecologic, 271-292 577-578
head and neck tumors, 317-336 early studies of, 622-624
in graft monitoring, bile, 661 E-mail, in result reporting, 243-244
exfoliative, 743-744 Echinococcus cyst, liver, cytology in, 343
pancreatic juice, 663 Education, in laboratory accreditation, 788—
urinary sediment, 744-749 790
in leukemia, 469-499 Effusion cytology, 443-467
in lymphoma, 469-499 diagnostic accuracy of, 444-445
kidney, 381-387 in adenocarcinoma, 450-451
liver, 336-344 in extramedullary hematopoiesis, 462
needle aspiration in. See Needle aspira- in infections, 462
tion. in leukemia, 454-456
pancreas, 344-352 in lymphoma, 454-456, 460
prostate, 387-393 in malignancy, 448—457
pulmonary, 293-315 in melanoma, 457
salivary glands, 325-332, 334 in mesothelial hyperplasia, 446-448
sputum, 294-295 in mesothelioma, 448, 457-460
stomach, 415-424 in poorly differentiated malignancy, 460-—
testis, 393-394 461
in primary site prediction, 461—462
thyroid, 317-324, 334
in rheumatoid disease, 462
urinary, 369-381
Cytomegalovirus infection, cytology in, in sarcoma, 456-457, 460
in small-cell carcinoma, 451, 454
colitis, 429-430
in squamous cell carcinoma, 451
pulmonary, 311
in trauma, 463
in transplant patients, 716-718, 720-722,
in undifferentiated large-cell carcinoma,
725, 728-729
454
liver, vs. rejection, 657, 660-661
lymphokine assay in, 750-752 preparatory methods for, 443-444
Eggs, detection of, in cysticercosis, 1018—
1020
Electron microscopy, in free-living amebic
infections, 864-865, 869
D’Antoni’s iodine, in amebiasis diagnosis,
Electronic systems. See Computers;
838-839 Information systems.
Data base, access to, 129-130
Electrophoresis, gel. See Gel
centralized, 223-224 electrophoresis.
Data management. See Information systems.
ELISA. See Enzyme-linked immunosorbent
Decision-oriented test request forms, 255- assay.
265 Encephalitis, amebic, from Naegleria
Degenerative changes, in liver graft, 658 fowleri, 861-866
Delta checking, in information systems, granulomatous, 866-870
100-101 toxoplasmic, 934-935
Density gradient separation, in lymphocyte Endocervical adenocarcinoma, cytology in,
isolation, for crossmatch procedures,
282-286
605 Endocervical dysplasia, cytology in, 283-284
Dermatitis, Acanthamoeba in, 870 Endocervical smears, sampling for, 273
Diarrhea, in cryptosporidiosis, 882-883 Endolimax nana, 829, 845
Dientamoeba fragilis, 829, 843, 845, 847 Endometrium, adenocarcinoma of, cytology
Direct agglutination test, in leishmaniasis, in, 286-289
920 hyperplasia of, cytology in, 286-287
in toxoplasmosis, 928-929 out-of-phase cells in, 287
DNA probes, in amebiasis, 854 smear sampling from, 273
Donor-specific antibodies. See under Endomyocardial biopsy, in heart graft
Antibody(ies). monitoring, 663-664, 742
Dot blot analysis, in HLA analysis, 515 Endoscopic retrograde pancreatography,
Dyskeratocytes, in cervical lesions, 281 cytologic specimens from, 344-345
Dyslipoproteinemia, expert systems for, 145 Endothelial antigens, antibodies to, in heart
Dysplasia/carcinoma in situ classification, of transplantation, 587-588
cervical lesions, 276 characteristics of, 628-629
1076 CUMULATIVE INDEX 1991
Endothelial antigens (Continued) Exfoliative cytology, in transplant recipient
in transplantation testing, 576-578 monitoring, 743-744
early studies of, 622-624 EXPERT expert system, 138, 142
skin crossmatch procedures for, 625- Expert systems, in laboratory information
629 system, 135-151
Entamoeba coli, 829, 838, 843, 844, 847 Eye, toxoplasmosis manifestations in, 925,
Entamoeba hartmanni, 829, 837-838, 844— 934
847
Entamoeba histolytica. See Amebiasis,
parasite of.
Entamoeba polecki, 829, 845-847 FAB classification, of leukemia, 473-475
Enzyme immunoassay, in American Falcon assay screening test (FAST) enzyme-
trypanosomiasis, 907 linked immunosorbent assay, in
in toxoplasmosis, 929-930 schistosomiasis, 1031-1034
Enzyme-linked immunoelectrotransfer blot Fat necrosis, of breast, cytology in, 358
test, in cysticercosis, 1016-1017 Fecal specimen. See Stool examination.
in schistosomiasis, 1034-1035 Fibroadenoma, of breast, cytology in, 360
Enzyme-linked immunosorbent assay Fibrocystic mastopathy, cytology in, 359
(ELISA), Falcon assay screening test Filariasis, diagnosis of, 977-1010
(FAST), in schistosomiasis, 1031-1034 approaches to, 1005-1007
in amebiasis, 852-854 immunologic, 993-1001
in anti-OKTS3 antibody detection, 707-708 antibody detection in, 994-995, 998,
in cysticercosis, 1016 1002, 1005
in filariasis, 995, 998 antigen detection in, 999-1000, 1005
in giardiasis, 821-823 molecular probes in, 1000
in leishmaniasis, 919-920 lymphatic type, 994-995, 998-1000
in toxoplasmosis, 929 onchocerciasis, 1001-1002, 1005
Enzyme-multiplied immunoassay, in parasitologic, 978-991
cyclosporine A monitoring, 678 bloodborne microfilariae detection in,
Eosinophilia, in liver graft rejection, 662 979-981
centrifugal concentration in, 981
Epithelial antigens, in transplantation
identification methods in, 985, 988,
testing, 576-578
Epithelial repair, cytology in, in esophageal
membrane filtration concentration in,
inflammation, 406-407
981-984
in stomach inflammation, 415-417
skin microfilariae detection in, 984—
Epitopes, private, in HLA
985
alloimmunization, 552-555
specimen collection for, 978-979
public, in HLA alloimmunization, 552-
stained blood smear in, 979
555
parasites of, 977-978
Epstein-Barr virus infection, in transplant
morphology of, 985, 988, 991
patients, 717-718, 721-722, 727 Fine needle aspiration biopsy. See Needle
Erythropoietin, in donor-specific antibody
aspiration.
development prevention, 582 Flotation techniques, for fecal specimen
Esophageal disorders, cytology in, 404-415 concentration, 841-843
adenocarcinoma, 408-409
Flow cytometry, in free OKT3 antibody
Barrett's dysplasia, 412-413 detection, 706
Barrett’s esophagus, 407-408 in graft monitoring, 739-740, 742-743
candidiasis, 404 in leukemia/lymphoma cytology, 475. See
chemotherapy injury, 411-412 also specific type under Lymphoma
epithelial repair, 406-407 and Leukemia.
gastroesophageal reflux, 406-407, 414- in malaria diagnosis, 949-950
415 in T-cell detection, in OKT3 therapy,
herpes esophagitis, 404-406 704-706
pemphigus vulgaris, 414 in transplantation crossmatching, 610-615
radiation esophagitis, 411-412 in urinary cytology, 381
squamous cell carcinoma, 409-410 Fluorescence activated cell sorter, in graft
squamous cell dysplasia, 413-414 monitoring, 739-740
undifferentiated carcinoma, 414 Fluorescence polarization immunoassay, in
ESPRE expert system, 142 cyclosporine A monitoring, 677-678
CUMULAITNDIEXV 1E99 1 1077
Fluorescent microscopy, in malaria Giemsa stain, in pneumocystosis diagnosis,
diagnosis, 947-948
Focal nodular hyperplasia, of liver, cytology Gleason grading, for prostate cancer, 388
in, 340 Glucagonoma, cytology in, 350-351
Follicular adenoma, thyroid, cytology in, Glycerol, for worm clearing, 1048-1049
318-319 Goiter, cytology in, 318
Follicular carcinoma, thyroid, cytology in, Government, in laboratory regulation, 795-
319 800
Formalin-ether sedimentation technique, for Graft rejection, ABO antigen effects on,
fecal specimen concentration, 841 537-550
Formalin solutions, for stool specimens, accelerated, heart, atherosclerosis in, 589
835-836 kidney, 585
FORTRAN, 6-7, 30-31, 56, 68-69 anti-idiotypic antibodies in. See Anti-idi-
Free antibody test, in OKT3 therapy, 706 otypic antibodies.
Fungal infections, cytology in, esophageal, crossmatching in, 766-768
404 delayed hyperacute, kidney, 583, 585
pulmonary, 311-312 donor-specific antibodies in. See Anti-
in transplant patients, 724 body(ies), in transplantation, donor-
specific.
histocompatibility matching in, 763-766
HLA-Cw in, 581
Gamma interferon, in endothelial antigen HLA influence on, 537-550
studies, 627 clinical matching techniques and, 541-
Gastrinoma, cytology in, 350-351 543
Gastritis, cytology in, 415-416, 420, 423- immune recognition in, 539-540
424 immunogenic determinants of, 540-541
Gastroesophageal reflux, cytology in, 406- presensitization and, 543-544
407, 414-415 human monocyte antigen system in, 538
Gastrointestinal cytology, 403-441 hyperacute, heart, 586-587, 589
esophagus, 404-415 kidney, 583
large intestine, 424-436 liver, 591, 593
stomach, 415-424 pancreas, 595
immunosuppressive therapy monitoring
Gel-diffusion precipitins, in amebiasis, 851-
in, 767-768
852
monitoring of, 653-670
Gel electrophoresis, in endothelial antigen
exfoliative cytology in, 743-744
characterization, 628-629
fine needle aspiration biopsy in, 743-
in HLA class I analysis, 514 744
one-dimensional isoelectric focusing,
heart, 663-664, 742-743
518
heart-lung, 664-665
Genitourinary cytology, 369-401
kidney, 735-738, 744-749
prostate, 387-393
urinary sediment cytology in, 744—
renal, 381-387 749
testis, 393-394 liver. See under Liver transplantation.
urinary, 369-381 lung, 664-665
Germ cell tumors, testicular, cytology in, lymphocyte surface markers in, 739-
393-394 741
Giardiasis, 811-827 pancreas, 663
chronic, 818 non-HLA antigens in. See Antigen(s),
clinical presentation of, 818 non-HLA.
diagnosis of, 818-821 OKTS therapy in. See OKT3 monoclonal
experimental approaches in, 823 antibodies.
immunologic methods in, 821-823 pathology in, heart, 586-587, 589
epidemiology of, 816-818 kidney, 583, 585
parasite of, antigens to, 822-823 liver, 591, 593
biology of, 811-813
pancreas, 595
life cycle of, 816 therapy monitoring in, 693-714
morphology of, 813, 816 urinary sediment cytology in, 744-749
taxonomy of, 811-813 vascular endothelial cell antigen system
transmission of, 816-817 in, 538
1078 CUMULATIVE INDEX 1991
Graft rejection (Continued) Hemangioma, cavernous, of liver, cytology
with negative lymphocyte crossmatch, 622 in, 340
Granular cell tumor, of breast, cytology in, Hematology, expert systems for, 144-145
360 Hematopoiesis, extramedullary, effusion
Granulocytic sarcoma, cytology in, 488-489 cytology in, 462
Granuloma, liver, cytology in, 343 Hematoxylin stain, for worms, 1049-1050
Granulomatous amebic encephalitis, 866- Hemosiderin, in pulmonary cytology, 312-
869 313
Granulomatous reactions, of lung, cytology Hepatitis, in transplant patients, 657, 660,
in, 312 718, 723, 727
Gynecologic cytology, 271-292 Hepatocellular adenoma, cytology in, 340
Bethesda system for, 273-279 Hepatocellular carcinoma, cytology in, 337—
combined cervicovaginal smear in, 272 338
endocervical sampling in, 273, 283-284 Hepatocytes, cytology of, 337
endometrial sampling in, 273 Herpes simplex virus infections, in
in chlamydial infection, 282 transplant patients, 717, 721-722
in endocervical adenocarcinoma, 282-286 Herpes virus infections, cytology in,
in endometrial lesions, 286-289 esophageal, 404-406
in extrauterine adenocarcinoma, 289-290 pulmonary, 311
in human papillomavirus lesions, 281-282 Herpesvirus type 6 infection, in transplant
in inflammatory conditions, 280-282 patients, 717, 720
in squamous preneoplastic/early neoplastic High performance liquid chromatography, in
lesions, 273-280 cyclosporine A monitoring, 675-676
sample adequacy for, 273 Histiocytic infiltration, of stomach, cytology
techniques for, 272-273 in, 420
two-smear method for, 272 Histologic studies, in cryptosporidiosis, 883
V-C-E smears for, 272-273 HIV infection. See Human
Gynecomastia, cytology in, 362 immunodeficiency virus infection.
HLA, 509-536
alloimmunization to. See under Alloim-
munization.
Hashimoto's thyroiditis, cytology in, 323- antibodies to. See also Antibody(ies), in
324 transplantation, donor-specific.
Head and neck tumors, cytology in, 317- posttransplant, 588-589
336 class I, cellular subtypes of, 518
cystic lesions, 334-335 crossreactivity of, 516-517
metastasis, 334 functions of, 511
paraganglioma, 333 in kidney graft rejection, 736
salivary glands, 325-332 in liver graft rejection, 660, 662
schwannoma, 332-333 polymorphisms of, definitions of, 515-
soft-tissue, 336 522
thyroid, 317-324, 334 structural basis for, 519-522
Health Industry Business Communications private antigen detection in, 517-518
Council, bar code standards of, 236-237 soluble, interference with anti-idiotypic
Health Level 7 Standard, for information antibody detection, 642
systems, 223, 240 structure of, 510
“Heart failure cells,” in pulmonary cytology, typing of, 512-513
312 class II, functions of, 511
Heart-lung transplantation, graft monitoring in liver graft rejection, 660
in, 664-665 polymorphisms of, definitions of, 522—
Heart transplantation, donor-specific 531
antibodies in, 585-589 structural basis for, 529-531
graft monitoring in, 663-664, 742-743 structure of, 510-511
Heidenhain’s iron alum-hematoxylin, in typing of, 513
amebiasis diagnosis, 843 genetic basis of, 510-512
HELP system, 140 genotyping of, 542
Hemagglutination test, indirect, in haplotyping of, 542-543
amebiasis, 851 mismatching of. See Mismatch, in trans-
in American trypanosomiasis, 906 plantation.
in toxoplasmosis, 928 polymorphisms of. See also specific class.